Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KAT2B | Q92831 | 5/20 | 0.65 |
| ▸ | KAT2A | Q92830 | 4/20 | 0.65 |
| ▸ | EP300 | Q09472 | 3/20 | 0.62 |
| ▸ | MPI | P34949 | 14/20 | 0.57 |
| ▸ | PMM2 | O15305 | 11/20 | 0.57 |
| ▸ | G6PD | P11413 | 8/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.57 |
| ▸ | MAPT | P10636 | 5/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.57 |
| ▸ | APOBEC3G | Q9HC16 | 5/20 | 0.57 |
| ▸ | PKM | P14618 | 4/20 | 0.57 |
| ▸ | HPGD | P15428 | 4/20 | 0.57 |
| ▸ | ALOX12 | P18054 | 4/20 | 0.57 |
| ▸ | MEN1 | O00255 | 2/20 | 0.57 |
| ▸ | POLB | P06746 | 2/20 | 0.57 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21687131 | 0.79 | KAT2B (1.00) | KAT2BKAT2AEP300MPIPMM2 | |
| SCHEMBL1897468 | 0.77 | KAT2B (1.00) | KAT2BKAT2AEP300MPIPMM2 | |
| SCHEMBL26645038 | 0.73 | MPI (0.72) | KAT2BKAT2AEP300MPIPMM2 | |
| SCHEMBL1904049 | 0.71 | KAT2B (0.55) | KAT2BKAT2AEP300MPIPMM2 | |
| SCHEMBL1906226 | 0.71 | MPI (0.55) | KAT2BKAT2AEP300MPIPMM2 | |
| SCHEMBL21687124 | 0.71 | KAT2A (0.68) | KAT2BKAT2AEP300MPIPMM2 | |
| SCHEMBL1908012 | 0.71 | KAT2B (0.54) | KAT2BKAT2AEP300MPIPMM2 | |
| SCHEMBL12297905 | 0.70 | KAT2B (1.00) | KAT2BKAT2AEP300MPIPMM2 | |
| SCHEMBL8370675 | 0.70 | MPI (0.61) | KAT2BKAT2AEP300MPIPMM2 | |
| SCHEMBL8372604 | 0.70 | MPI (0.72) | KAT2BKAT2AEP300MPIPMM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210060051-A1 | COMBINED MODALITIES FOR NUCLEOSIDES AND/OR NADPH OXIDASE (NOX) INHIBITORS AS MYELOID-SPECIFIC ANTIVIRAL AGENTS | EMORY UNIVERSITY | 2021-03-04 | — | — | US | claimed |
| EP-3732180-A1 | COMBINED MODALITIES FOR NUCLEOSIDES AND/OR NADPH OXIDASE (NOX) INHIBITORS AS MYELOID-SPECIFIC ANTIVIRAL AGENTS | Emory University (US) | 2020-11-04 | — | — | EP | claimed |
| WO-2011062864-A2 | INHIBITORS OF NOX ENZYMES AND METHODS OF USE THEREOF | EMORY UNIVERSITY (US) | 2011-05-26 | — | — | WO | claimed |
| EP-3980400-B1 | PEPTIDOMIMETICS FOR THE TREATMENT OF CORONAVIRUS AND PICORNAVIRUS INFECTIONS | UNIV EMORY (US) | 2025-08-06 | — | — | EP | disclosed |
| US-20250114389-A1 | NUCLEOSIDES AND NUCLEOTIDES ANALOGS AS ANTIVIRAL AGENTS | UNIV EMORY (US) | 2025-04-10 | — | — | US | disclosed |
| US-12268723-B2 | Peptidomimetics for the treatment of coronavirus and picorna virus infections | EMORY UNIVERSITY (US) | 2025-04-08 | — | — | US | disclosed |
| US-20240238323-A1 | MODIFIED NUCLEOSIDES AND NUCLEOTIDES ANALOGS AS ANTIVIRAL AGENTS FOR CORONA AND OTHER VIRUSES | EMORY UNIVERSITY | 2024-07-18 | — | — | US | disclosed |
| US-20240216413-A1 | THIONUCLEOSIDES AS ANTIVIRAL AGENTS | EMORY UNIVERSITY (US) | 2024-07-04 | — | — | US | disclosed |
| CN-117881403-A | Thionucleosides as antiviral agents | 爱莫里大学 | 2024-04-12 | — | — | CN | disclosed |
| CN-117858711-A | Nucleoside and nucleotide analogs as antiviral agents | 爱莫里大学 | 2024-04-09 | — | — | CN | disclosed |
| CN-117769427-A | Modified nucleosides and nucleotide analogues as antiviral agents for coronaviruses and other viruses | 埃默里大学 | 2024-03-26 | — | — | CN | disclosed |
| WO-2022170396-A1 | AGENTS AND METHODS FOR THERAPY AND PROPHYLAXIS | ViraLok Therapeutics Pty Ltd (AU) | 2022-08-18 | — | — | WO | disclosed |
| EP-3980400-A1 | PEPTIDOMIMETICS FOR THE TREATMENT OF CORONAVIRUS AND PICORNAVIRUS INFECTIONS | Emory University (US) | 2022-04-13 | — | — | EP | disclosed |
| CN-114026067-A | Peptide mimetics for the treatment of coronavirus and picornavirus infections | 埃默里大学 | 2022-02-08 | — | — | CN | disclosed |
| US-11207370-B2 | Peptidomimetics for the treatment of coronavirus and picornavirus infections | EMORY UNIVERSITY (US) | 2021-12-28 | — | — | US | disclosed |
| US-20210060051-A1 | COMBINED MODALITIES FOR NUCLEOSIDES AND/OR NADPH OXIDASE (NOX) INHIBITORS AS MYELOID-SPECIFIC ANTIVIRAL AGENTS | EMORY UNIVERSITY | 2021-03-04 | — | — | US | disclosed |
| US-20210008150-A1 | PEPTIDOMIMETICS FOR THE TREATMENT OF CORONAVIRUS AND PICORNAVIRUS INFECTIONS | EMORY UNIVERSITY | 2021-01-14 | — | — | US | disclosed |
| WO-2020247665-A1 | PEPTIDOMIMETICS FOR THE TREATMENT OF CORONAVIRUS AND PICORNAVIRUS INFECTIONS | EMORY UNIVERSITY (US) | 2020-12-10 | — | — | WO | disclosed |
| EP-3732180-A1 | COMBINED MODALITIES FOR NUCLEOSIDES AND/OR NADPH OXIDASE (NOX) INHIBITORS AS MYELOID-SPECIFIC ANTIVIRAL AGENTS | Emory University (US) | 2020-11-04 | — | — | EP | disclosed |
| WO-2011062864-A2 | INHIBITORS OF NOX ENZYMES AND METHODS OF USE THEREOF | EMORY UNIVERSITY (US) | 2011-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240216413-A1 | THIONUCLEOSIDES AS ANTIVIRAL AGENTS | MTAP, NSUN3, METTL3 | KAT2B 3549/4885KAT2A 2125/4885EP300 1238/4885 |
| US-20210060051-A1 | COMBINED MODALITIES FOR NUCLEOSIDES AND/OR NADPH OXIDASE (NOX) INHIBITORS AS MYELOID-SPECIFIC ANTIVIRAL AGENTS | NOX1, NOX3, NOX4 | KAT2B 1275/4885KAT2A 1897/4885EP300 1632/4885 |
| US-20210008150-A1 | PEPTIDOMIMETICS FOR THE TREATMENT OF CORONAVIRUS AND PICORNAVIRUS INFECTIONS | ACE2, SARS1, VIP | KAT2B 4724/4885KAT2A 4561/4885EP300 3393/4885 |
| US-12268723-B2 | Peptidomimetics for the treatment of coronavirus and picorna virus infections | ACE2, SARS1, HAVCR2 | KAT2B 4726/4885KAT2A 4465/4885EP300 3526/4885 |
| US-20250114389-A1 | NUCLEOSIDES AND NUCLEOTIDES ANALOGS AS ANTIVIRAL AGENTS | PNP, MTAP, NOP2 | KAT2B 4681/4885KAT2A 3950/4885EP300 3058/4885 |
| US-20240238323-A1 | MODIFIED NUCLEOSIDES AND NUCLEOTIDES ANALOGS AS ANTIVIRAL AGENTS FOR CORONA AND OTHER VIRUSES | MTAP, PNP, SARS1 | KAT2B 4594/4885KAT2A 3400/4885EP300 3343/4885 |
| US-11207370-B2 | Peptidomimetics for the treatment of coronavirus and picornavirus infections | ACE2, SARS1, VIP | KAT2B 4724/4885KAT2A 4561/4885EP300 3393/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.